Spectranetics (SPNC) Announces CE Mark Approval for ThromCatXT

June 23, 2009 7:05 AM EDT

Spectranetics Corporation (Nasdaq: SPNC) received the CE mark approval for its next-generation ThromCat XT Thrombus Removal System, a single-use, disposable device indicated for mechanical removal of thrombus from native coronary arteries and infra-inguinal arteries.

The launch of the product will commence immediately within the European Union.

The approval triggers a milestone payment of $1.5 million pursuant to the Company's Amended Development and Regulatory Services agreement with Kensey Nash Corporation (Nasdaq: KNSY).


Related Categories

FDA

Stocks Mentioned

KNSY 22.36

-0.79 -3.41%
Volume: 64,826
Track KNSY

SPNC 5.89

-0.07 -1.17%
Volume: 14,739
Track SPNC


Add Your Comment